JPWO2021123173A5 - - Google Patents

Claims (15)

A fusion protein comprising an IL-37 polypeptide and an antibody Fc region, wherein the amino acid sequence of the IL-37 polypeptide is
an amino acid residue selected from the group consisting of serine, threonine, glycine, alanine, glutamine and asparagine at amino acid position 181;
an amino acid residue selected from the group consisting of serine, threonine, glycine, alanine, glutamine and asparagine at amino acid position 183; and an amino acid residue selected from the group consisting of serine, threonine, glycine, alanine, glutamine and asparagine. A fusion protein containing amino acid position 207. 2. The fusion protein of claim 1, comprising serine at amino acid positions 181, 183 and 207. The fusion protein according to claim 1 or 2, which is an anti-inflammatory fusion protein. A fusion protein according to any one of claims 1 to 3, wherein the amino acid sequence of the IL-37 polypeptide comprises amino acids 46 to 218. Claim 1, wherein the IL-37 polypeptide has at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% or 94% sequence identity with SEQ ID NO: 1. The fusion protein according to any one of 4 to 4. 6. The fusion protein of any one of claims 1 to 5, wherein the IL-37 polypeptide further comprises an additional disulfide bridge compared to the wild-type IL-37 polypeptide. Fusion protein according to any one of claims 1 to 6, wherein the Fc region of the antibody is an IgG, preferably an IgG1 Fc region. 8. The fusion protein of any one of claims 1 to 7, wherein the amino acid sequence of the IL-37 polypeptide comprises an alanine located at amino acid position 85. A pharmaceutical composition comprising a fusion protein according to any one of claims 1 to 8. 10. A pharmaceutical composition according to claim 9 for use in the treatment or prevention of inflammatory diseases or conditions. The inflammatory disease or condition is selected from the group consisting of inflammatory bowel disease; lupus erythematosus; arthritis; preferably rheumatoid arthritis; psoriasis, allergic rhinitis; Graves'disease; ankylosing spondylitis; preferably myocardial infarction and stroke. 11. Selected from the group consisting of ischemia reperfusion injury; asthma; periodontitis; diabetes and metabolic syndrome; cancer, preferably solid cancer types, and atherosclerosis and Behcet's disease. Pharmaceutical composition of. 12. The pharmaceutical composition of claim 11, wherein the inflammatory disease or condition is inflammatory bowel disease. A nucleic acid molecule encoding a fusion protein according to any one of claims 1 to 8. A vector comprising the nucleic acid molecule according to claim 13. A cell comprising a nucleic acid molecule according to claim 13 or a vector according to claim 14.